Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Core Viewpoint - Lisata Therapeutics, Inc. has entered into a binding term sheet for acquisition by Kuva Labs, Inc., with a cash offer of $4.00 per share, representing an approximate 85% premium over Lisata's recent closing stock price [1][2] Group 1: Acquisition Details - Kuva will commence a tender offer to purchase all outstanding shares of Lisata at $4.00 per share in cash [1] - Stockholders will receive two contingent value rights (CVRs) valued at $1 each, contingent upon specific milestones related to the drug certepetide [1][2] - The acquisition has been unanimously approved by the boards of directors of both companies, with a definitive purchase agreement expected before February 27, 2026 [1] Group 2: Product Information - Certepetide is an investigational drug designed to enhance the delivery of anti-cancer therapies to solid tumors, showing favorable safety and clinical activity in trials for pancreatic cancer [4][5] - The drug has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers, indicating its potential in treating serious diseases [4][5] Group 3: Company Background - Lisata Therapeutics focuses on developing innovative therapies for advanced solid tumors and has established partnerships based on its CendR Platform technology [5] - Kuva Labs is a preclinical bioscience company developing the NanoMark direct MR imaging platform, aimed at improving cancer detection and treatment [7]